{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT02200978: Phase 4 Interventional Completed Childhood Acute Promyelocytic Leukemia
(2011)
Source URL:
First approved in 2023
Source:
M016
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M016
(2023)
Source URL:
First approved in 2023
Source:
M016
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M032
(2025)
Source URL:
First approved in 2022
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Deshiyou by Shenzhen Deyintang Biotechnology Co., Ltd.
(2022)
Source URL:
First approved in 2022
Source:
Deshiyou by Shenzhen Deyintang Biotechnology Co., Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
AAWESOME SCALP ESSENCE by AAWESOMEKOREA Co., Ltd.
(2022)
Source URL:
First approved in 2022
Source:
AAWESOME SCALP ESSENCE by AAWESOMEKOREA Co., Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card by Chuanzongbao (Hangzhou) intangible cultural heritage protection Co., Ltd
(2021)
Source URL:
First approved in 2021
Source:
Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card by Chuanzongbao (Hangzhou) intangible cultural heritage protection Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 341
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 341
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2019)
Source URL:
First approved in 2019
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE